Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
about
Posaconazole: an oral triazole with an extended spectrum of activityFactors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantationImpact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafineUltra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case ReportPharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteersNew and investigational triazole agents for the treatment of invasive fungal infections.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Comparison of clinical pharmacology of voriconazole and posaconazole.Use of posaconazole in the treatment of invasive fungal infections.Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.Posaconazole: when and how? The clinician's view.Reaction phenotyping to assess victim drug-drug interaction risks.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.Posaconazole: a next-generation triazole antifungal.Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient VariabilityPosaconazole: An Update of Its Clinical Use.Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.[Candida infections in the elderly].Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection.The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension.
P2860
Q28291282-166DF4A3-0BFE-48B4-A9CF-BAC8BA2D3F78Q33559111-225230C6-F4AC-431B-8921-A623C4ADB438Q33726698-402CFF41-F684-4C91-9EAF-1F7E4701CCBEQ34108650-EDD834FC-6AAE-4FB2-BCE5-79B8E340F6C4Q34160621-89D27ABA-9992-4DBD-82FB-137264B4462CQ34309527-3D0E5550-B9C7-4444-B5B4-26B8621A3595Q36364013-591160DC-82F9-4793-B297-A299D21E0854Q36396203-CBEC12D0-7B43-4FC3-8060-49CC517C1DFEQ37020761-AFB2E99C-CE06-4AC8-8D23-E3A6CF552D27Q37115829-378D7381-2F84-4CAA-9E92-0154A276D7BBQ37247780-008D3BB8-1AA0-415B-A435-CD9F7A06391AQ37364295-C7D6C2E4-C901-465B-9329-D71C591E9D4EQ37404840-5D9F6F94-33B5-4E18-AD5D-D0758F960EDAQ37727651-631F6D52-413D-49B6-943E-7D4574491170Q37810083-89470BBB-F91F-497C-9D75-8CBCB5DA39F8Q37813420-A845EF3F-0FAA-4EAD-9760-A4B5CCEA877DQ37901534-3B325891-E741-4D59-B519-F27E66C3EA30Q38640403-74220885-0B5B-4F26-9ACD-A08EA6ED3046Q38816614-BDA0D6FA-4BCC-40C3-829B-991C8588C258Q38866474-BFB1FA02-A675-4471-A03C-7BD5EF091B45Q40188974-BE625E55-74A9-4C38-80CE-4CA345BE910EQ40517272-3C7B241B-DD19-48F4-898A-C0BD8FEEBCE6Q41848545-68930997-19DD-4E79-BDF0-EE8B66C0C35DQ41991703-FD25045F-9BE9-4F6B-B572-DEA934E789ABQ42144246-8E1B599D-55DC-4D68-933A-E4ABA13299A2Q42413286-6DC1843B-AE97-4E39-8DD2-3D14CA1ADF5CQ44162406-634D3915-EEF3-4DCC-92E3-00CDEE7CF453Q45064389-293652E2-8753-438D-ADA5-BC03C23F223CQ46341880-CAA0A205-5AD9-4F61-8909-A1EB53659A49Q46879963-49CEECC2-6B74-42AF-BC1B-C719F665398AQ50049061-610C2937-81DB-4598-80DE-B29CC0131049Q51579656-F44E85F9-C023-4ADC-91AA-5AB6A844CD64Q52777337-083AB7CA-B91C-48CF-A9EE-AC6ABCB3B3A4Q53073458-131338D4-E7F5-4691-BC00-4AE215BDFAFB
P2860
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Effects of age, gender, and ra ...... onazole in healthy volunteers.
@ast
Effects of age, gender, and ra ...... onazole in healthy volunteers.
@en
type
label
Effects of age, gender, and ra ...... onazole in healthy volunteers.
@ast
Effects of age, gender, and ra ...... onazole in healthy volunteers.
@en
prefLabel
Effects of age, gender, and ra ...... onazole in healthy volunteers.
@ast
Effects of age, gender, and ra ...... onazole in healthy volunteers.
@en
P2093
P2860
P356
P1476
Effects of age, gender, and ra ...... onazole in healthy volunteers.
@en
P2093
Angela Sansone-Parsons
B Kantesaria
Gopal Krishna
Jason Simon
Jerry Herron
Peter Soni
Randall Stoltz
P2860
P304
P356
10.1128/AAC.00472-06
P407
P577
2006-11-13T00:00:00Z